Efavirenz (EFV) Intensification

Completed · Phase 4

Conditions studied: HIV

In brief

The goal of this clinical trial is to see if Efavirenz (EFV) intensification to a baseline combination antiretroviral regimen (cART) can help reduce the size of the latent reservoir in people living with HIV (PLWH). The main questions this study aims to address are: 1. is the addition of EFV to a cART regimen safe and well tolerated? 2. Is there a reduction in the blood and tissue HIV reservoir after intensification? Researchers will compare each participants reservoir size prior to and post EFV intensification.

Key facts

Study ID

NCT07193875

Run by

Washington University School of Medicine

People needed

9

Starts

2023-02-09

Expected to finish

2024-12-16

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age
• Diagnosis of HIV
• Documentation of at least two historical HIV-1 RNA viral load measurements <500 copies/mL while on ART obtained by standard assay.
• No known non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations.
• Currently on a stable regimen including an integrase strand transfer inhibitor (INSTI) and two nucleoside reverse transcriptase inhibitors (NRTI). Receiving the current regimen for at least 90 days prior to study entry with no intention to change for the duration of the study.

You may not qualify if…

• Untreated depression, defined as a Patient health questionnaire 9 (PHQ-9) score > 15 at time of enrollment
• Known prior NNRTI resistance, or INSTI resistance.
• Cytochrome 450 polymorphism resulting in rapid or delayed metabolism of Efavirenz
• Not currently on a PI based regimen.
• Does not have an immunocompromising medical condition. (ie malignancies particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment).
• Chronic, acute, or recurrent infections that are current and serious, in the opinion of the site investigator.
• Breastfeeding patients as well as those whom are pregnant or plan to become pregnant during period of the study.
• Those with active Hepatitis C or Hepatitis B.

Where it is running

• Washington University in St Louis — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.